94 related articles for article (PubMed ID: 20064686)
1. GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro.
Bellyei S; Schally AV; Zarandi M; Varga JL; Vidaurre I; Pozsgai E
Cancer Lett; 2010 Jul; 293(1):31-40. PubMed ID: 20064686
[TBL] [Abstract][Full Text] [Related]
2. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
[TBL] [Abstract][Full Text] [Related]
4. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
[TBL] [Abstract][Full Text] [Related]
6. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo.
Yu J; Qian H; Li Y; Wang Y; Zhang X; Liang X; Fu M; Lin C
Gynecol Oncol; 2007 Aug; 106(2):400-6. PubMed ID: 17512576
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
[TBL] [Abstract][Full Text] [Related]
10. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.
Pozsgai E; Schally AV; Hocsak E; Zarandi M; Rick F; Bellyei S
Int J Oncol; 2011 Oct; 39(4):1025-32. PubMed ID: 21701777
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
[TBL] [Abstract][Full Text] [Related]
12. A correlation of endocrine and anticancer effects of some antagonists of GHRH.
Kovács M; Schally AV; Hohla F; Rick FG; Pozsgai E; Szalontay L; Varga JL; Zarándi M
Peptides; 2010 Oct; 31(10):1839-46. PubMed ID: 20633588
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.
Köster F; Engel JB; Schally AV; Hönig A; Schröer A; Seitz S; Hohla F; Ortmann O; Diedrich K; Buchholz S
Breast Cancer Res Treat; 2009 Jul; 116(2):273-9. PubMed ID: 18629632
[TBL] [Abstract][Full Text] [Related]
14. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.
Wu HM; Huang HY; Schally AV; Chao A; Chou HH; Leung PC; Wang HS
Oncotarget; 2017 Jan; 8(3):4410-4421. PubMed ID: 28032599
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
[TBL] [Abstract][Full Text] [Related]
17. Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor.
Barabutis N; Siejka A; Schally AV; Block NL; Cai R; Varga JL
J Mol Endocrinol; 2010 Feb; 44(2):127-34. PubMed ID: 19897610
[TBL] [Abstract][Full Text] [Related]
18. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132.
Volakaki AA; Lafkas D; Kassi E; Schally AV; Papavassiliou AG; Kiaris H
J Mol Endocrinol; 2008 Nov; 41(5):389-92. PubMed ID: 18765563
[TBL] [Abstract][Full Text] [Related]
19. Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: I. In vitro studies of adhesion, migration and invasion of MDA-MB 231 human breast cancer cells.
Tantivejkul K; Vucenik I; Shamsuddin AM
Anticancer Res; 2003; 23(5A):3671-9. PubMed ID: 14666663
[TBL] [Abstract][Full Text] [Related]
20. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells.
Lee WJ; Chen WK; Wang CJ; Lin WL; Tseng TH
Toxicol Appl Pharmacol; 2008 Jan; 226(2):178-91. PubMed ID: 17961621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]